Delivery Order SPE2DB20D3103-SPE2DB22FM0Q1
- Not listed
- This federal contract award, valued at $4,447.88, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ketorolac 30 mg/ml vials, a pain management medication. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,066.91 firm fixed price delivery order is for the supply of Ketorolac 30 mg/ml vials, a pain management medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,299.44 firm fixed-price delivery order is for the supply of Ketorolac 30 mg/ml vials, a pain management medication. The contract has a completion date of November 7, 2024 and was awarded on November 6, 2024. This award is a part of AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award, valued at $1,569.49, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ketorolac 30 mg/mL vials, a pain management medication. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999.00. The IDC enables...
- This federal contract award is from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the delivery of Ketorolac 30 mg/ml vials, a medication used for pain management. The $1,985.51 firm-fixed price delivery order is part of a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical that runs through November 2026. This IDC enables Amerisourcebergen to provide a wide range of pharmaceutical products and medical supplies to support military healthcare...
- This federal contract award, valued at $1,163.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ketorolac 30 mg/ml vials, a medication used for pain management. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,163.76 firm fixed-price delivery order is for the supply of Ketorolac 30 mg/ml vials, a pain management medication. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,453.20 firm fixed-price delivery order is for the supply of 30 mg/mL ketorolac vials, a medication used for pain management. The contract has a completion date of December 8, 2023 and was not set aside for any specific business category. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,351.13 firm fixed-price delivery order is for the supply of ketorolac 30 mg/ml vial, a pain management medication. The contract, which does not have a set-aside designation, has an ultimate completion date of May 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of Ketorolac 30mg/ml 25s, a pain medication, to the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $1,029.16, is a firm fixed-price delivery order contract with a completion date of December 12, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FM0Q1Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,440.76 Firm Fixed Price delivery order is for the supply of Ketorolac 30 mg/ml vials, a pain management medication. The award is associated with a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This single-award IDC serves as the primary vehicle for Cencora, Inc. to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA IDC, Cencora, Inc. maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs. These IDCs demonstrate the company's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 12/21/21 |